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Background
➢ SETD8 is the only methyltransferase 
that is known to target and 
monomethylate lysine 20 in histone 
H4 (H4K20). H4K20 methylation by 
SETD8 hinders DNA replication by 
blocking acetylation in G1 phase, 
suppresses p53 activation in cancer 
cells, and SETD8 overexpression is 
present in different cancers.
➢ There are limited known inhibitors 
that bind to SETD8. Inhibitors may 
bind to the cofactor, substrate, or 
possible allosteric sites. Using the 
“fragment drug discovery” method, 
we are testing small compounds 
(fragments) to structurally analyze 
their binding mode to SETD8. 
Combining these fragments that bind 
in different sites of SETD8 could 
lead to better inhibitors that may be 
used in cancer treatments. 
➢ The construct of SETD8 containing 
the catalytic domain was used for 
the study.
Conclusions
➢ Further testing is required to know 
the exact binding location of the 
binding compounds.
➢ Using x-ray diffraction data from 
SETD8 crystals, we can better 
understand the binding location of 
possible inhibitors. We can use this 
data to modify the compounds in
the hopes that someday this 
information may lead to cancer 
treatment drugs.
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Methods
➢ SETD8 activity was measured 
using a bioluminescence assay 
(MTase-GloTM, Promega), in which 
the by-product SAH is converted 
into ATP and is detectable by 
luciferase reaction.
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Our collaborators used Differential 
Scanning Fluorimetry (DSF) and 
Surface plasmon resonance (SPR) 
to screen a library of compounds 
for possible binding inhibitors of 
SETD8
SETD8 overexpression in E. coli. 
Nickel affinity and size exclusion 
chromatography for purification
Protein crystallography and X-ray 
diffraction for structures and find 
binding location
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Results
Figure 1. A and B correspond to two of 
the strongest binding compounds used in 
this study, these compounds were 
provided by our collaborators3. C
corresponds to a confirmed binding 
inhibitor that has been proven to have high 
binding affinity to SETD81,2.
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Figure 2. Different time plots were 
measured after the second Ni column in a 
Coomassie gel that showed the added Ni 
His-tag being cut by a protease, leaving 
only purified SETD8. SETD8 appeared in 
the last lane between the 20kD-15kD 
which is accurate to the molecular weight 
of SETD8 (18743.13). The last band in the 
gel indicates the cut His-tag that stayed




Figure 3. A- To get a more accurate reading 
on our purified protein, we decided to take 
fractions that came off a preparative sizing 
column and put through an analytical 
column. B- Known markers including 
Myoglobin (17kD), γ-globulin (158kD), and 
Thyroglobulin (670kD). C- Gel of purified 
SETD8 determined to be a monomer with a 
size of 18kD.
➢We obtained approximately 150 
mg of purified protein from 2 L. 
After purifying SETD8 using size 
exclusion chromatography, we 
tried growing protein crystals with 
the purified protein under different 
conditions. 
➢No apo-crystals were formed using 
the long protein construct of SETD8. 
We were successful in producing 
crystals with protein and SAM 
cofactor using a citrate salt after 
screening hundreds of conditions 
that included several salts, buffers, 
and other precipitating agents. 
Figure 3. A- Using the sitting drop method, 
we obtained a small crystal using SETD8 
(16mg/mL) and SAM with a screen condition 
of 1.4M sodium citrate tribasic and .1M 
HEPES pH7.5. B- Improved protein crystal 
using SETD8(16mg/mL) and SAM in a 
screen condition of 1.2M sodium citrate 
tribasic and .1M HEPES pH7.6.
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Figure 4. Crystallization using condition 
referred in Figure 3.B was used along 
compound EML1046 (Figure 1.B). Results 
were inconclusive because crystals did not 
appear like the previous crystals. 
Produced crystals were not useful in the 
present form, we cannot confirm what the 
crystals are, but they might contain the 
binding compound tested. 
